Please login to the form below

Not currently logged in
Email:
Password:

Dicerna

This page shows the latest Dicerna news and features for those working in and with pharma, biotech and healthcare.

Boehringer adds to pipeline again with €628m Autifony CNS deal

Boehringer adds to pipeline again with €628m Autifony CNS deal

This is the second licensing deal for Boehringer in the last few weeks, coming after it added a non-alcoholic steatohepatitis (NASH) candidate from Dicerna in a $201m deal.

Latest news

  • Boehringer bolsters NASH pipeline with $201m Dicerna deal Boehringer bolsters NASH pipeline with $201m Dicerna deal

    Boehringer bolsters NASH pipeline with $201m Dicerna deal. Will investigate a “new therapeutic approach”to target liver functionality. ... Boehringer Ingelheim has added another drug candidate to its pipeline for non-alcoholic steatohepatitis (NASH)

  • 15 years since the first paper published on RNA interference 15 years since the first paper published on RNA interference

    Alnylam is also involved in collaborations with companies including Genzyme, the Medicines Company and Takeda, while other biotechs, such as Dicerna, RXi and Tekmira, all have their own programmes, demonstrating a

  • RNA interference rebirth RNA interference rebirth

    founder of RNAi company Dicerna. ... Most companies active in the RNAi field, such as Alnylam, Dicerna, RXi and big pharma players like Novartis and Merck, have elected to develop double-stranded, small interfering RNA (siRNA) oligonucleotides

  • Advancing acquisitions

    In particular, the deal between Dicerna and Kyowa Hakko, if extended from the currently agreed targets, could reach a value of $1.4bn. ... Another interesting feature of this deal is that Dicerna has secured an option to co-promotion rights.

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch - May 2017 Deal Watch - May 2017

    Investment. Dicerna (biotech). 70. M&A without debt. Private equity companies are in the minority compared to acquisitions made by pharmaceutical companies for strategic reasons such as new markets or technologies.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics